AIM-HIGH临床试验中进行和未进行DCE-MRI斑块测量的研究对象的临床和实验室数据总结。
Summary of clinical and laboratory data of study subjects with and without DCE-MRI plaque measurements in the AIM-HIGH clinical trial.
作者信息
O'Brien Kevin D, Hippe Daniel S, Chen Huijun, Neradilek Moni B, Probstfield Jeffrey L, Peck Suzanne, Isquith Daniel A, Canton Gador, Yuan Chun, Polissar Nayak L, Zhao Xue-Qiao, Kerwin William S
机构信息
Division of Cardiology, Department of Medicine, University of Washington, Seattle, WA, USA.
Department of Radiology, University of Washington, Seattle, WA, USA.
出版信息
Data Brief. 2016 Jan 2;6:476-81. doi: 10.1016/j.dib.2015.12.030. eCollection 2016 Mar.
This brief data article summarizes the clinical risk factors and laboratory data of a group of subjects recruited for the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides and Impact on Global Health Outcomes) and an associated magnetic resonance imaging (MRI) substudy. The sample is restricted to those on statin therapy at the time of enrollment and data are presented stratified by whether dynamic contrast enhanced MRI (DCE-MRI) markers of carotid plaque vascularity and inflammation were available or not. The data provided herein are directly related to the article "Longer Duration of Statin Therapy is Associated with Decreased Carotid Plaque Vascularity by Magnetic Resonance Imaging" [2].
这篇简短的数据文章总结了为AIM-HIGH试验（代谢综合征伴低高密度脂蛋白/高甘油三酯的动脉粥样硬化血栓形成干预及对全球健康结局的影响）招募的一组受试者的临床风险因素和实验室数据，以及一项相关的磁共振成像（MRI）子研究。样本仅限于入组时接受他汀类药物治疗的患者，并根据是否有颈动脉斑块血管生成和炎症的动态对比增强MRI（DCE-MRI）标记物进行分层呈现数据。本文提供的数据与文章《他汀类药物治疗时间延长与磁共振成像显示的颈动脉斑块血管生成减少相关》[2]直接相关。
Zotero 插件